Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05852431 · ClinicalTrials.gov registry record · Phase 3
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
A Phase 3 study of Severe Hypertriglyceridemia, sponsored by 89bio.
- Active
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT05852431 is a Phase 3 study of Severe Hypertriglyceridemia that is active but no longer recruiting, run by 89bio. The registered enrollment target is 360 participants, roughly in line with the 380-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target. The trial reports 20 study locations across 6 states.
The verdict
NCT05852431, a Phase 3 study of Severe Hypertriglyceridemia, is active but no longer recruiting, sponsored by 89bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pegozafermin
Study Locations (20)
California
- 89bio Clinical Trial Site - Huntington Park
- 89Bio Clinical Study Site - Long Beach
- 89bio Clinical Study Site - Los Angeles
- 89bio Clinical Trial Site - Northridge
- 89bio Clinical Trial Site - Panorama City
- 89bio Clinical Study Site - Santa Ana
- 89bio Clinical Trial Site - Santa Ana
- 89bio Clinical Study Site - Thousand Oaks
- 89Bio Clinical Study Site - Tustin
Arizona
- 89bio Clinical Study Site - Chandler
- 89bio Clinical Study Site - Peoria
- 89Bio Clinical Study Site - Tucson
Arkansas
- 89bio Clinical Study Site - Conway
- 89bio Clinical Study Site - Jonesboro
- 89bio Clinical Study Site - Little Rock
Colorado
- 89bio Clinical Study Site - Wheat Ridge
- 89bio Clinical Trial Site - Wheat Ridge
Florida
- 89Bio Clinical Study Site - Clearwater
- 89bio Clinical Study Site - Clearwater
Connecticut
- 89bio Clinical Study Site - Bridgeport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2026-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05852431
The ClinicalTrials.gov registry entry for NCT05852431 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 380-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target. The listed sponsor is 89bio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05852431 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05852431 about?
NCT05852431 is a clinical study titled "To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia". To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.
What is the current status of trial NCT05852431?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2023-06-15. Estimated completion is 2026-04.
What conditions does trial NCT05852431 study?
This clinical trial studies the following conditions: Severe Hypertriglyceridemia.
What interventions are being tested in trial NCT05852431?
The interventions under investigation include: Placebo (DRUG), Pegozafermin (DRUG).
Who is sponsoring clinical trial NCT05852431?
This trial is sponsored by 89bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05852431 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
RECRUITING · Phase 3
-
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
COMPLETED · Phase 3
-
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.